This international consensus and prioritisation exercise sought to define clinically relevant use cases for tuberculosis (TB) biomarkers and diagnostic tests spanning Mtb infection, active disease, treatment optimisation, and post‑TB care. The objective was to create a single, prioritised framework to focus biomarker discovery, guide investment, and inform future target product profiles, funding calls, and policy development.
A scoping review of 24 documents (including literature, guidelines, and existing target product profiles) produced 69 candidate use cases that were consolidated to 13 proposals for evaluation. The study applied a structured consensus approach to validate and prioritise these use cases so they more closely reflect the needs of care providers, public health programmes, researchers, developers and funders.
The methods combined a scoping review with a hybrid RAND/UCLA modified Delphi consensus technique. The scoping review identified and consolidated candidate use cases from 24 relevant documents into a reduced set suitable for stakeholder appraisal. The RAND/UCLA hybrid Delphi approach involved a staged process:
The 80% agreement threshold was pre‑specified for identifying items requiring further discussion in the consensus meeting.
The process engaged 185 identified interest‑holders representing a broad cross‑section of stakeholders: clinicians, researchers, diagnostic developers, industry, funders, civil society, national TB programmes, and policymakers, including representatives from the World Health Organization. Contributions were provided in a professional, anonymised capacity and analysed according to consensus method guidance.
No new patient data were generated; responses were anonymised and no sensitive personal data were collected. In line with published guidance for consensus methods, formal institutional ethical review was not required for this activity.
Following the consensus and validation meetings, eleven use cases were retained covering four stages of the TB care pathway:
The exercise reduced the consolidated 13 candidate use cases to eleven retained priorities following stakeholder input and discussion.
Stakeholders identified several highest‑priority use cases. These were emphasised as immediate areas where biomarkers and tests could have substantial clinical and public health impact:
Detection of drug‑resistant TB — prioritised because rapid, accurate identification of resistance informs appropriate regimen selection and reduces transmission risk.
Prediction of progression from Mtb infection to active disease — a test that can stratify risk of progression would enable targeted preventive therapy and resource allocation.
Identification of current Mtb infection — distinguishing current infection from remote exposure was prioritised to improve screening and preventive strategies.
Improved diagnosis of active TB disease — better diagnostics for active disease remain a core priority for case finding and timely treatment initiation.
By ranking these use cases, the consensus framework signals where diagnostic research and product development should focus to meet stakeholder needs.
The study declared that no competing interests were reported by the authors. The research was funded by the Wellcome Trust. The authors note that no new patient‑level data were produced and that consensus methods were conducted in line with guidance such that formal ethical approval was not required.
As a next step, the authors propose applying this prioritised framework to the current biomarker pipeline to identify mismatches between innovation and the highest clinical and public health priorities. The framework is intended to inform future target product profiles, funding calls, and policy development to improve translation of biomarker research into tools that impact patient and public health outcomes.
This initiative provides the first comprehensive, stakeholder‑endorsed, prioritised list of use cases for TB biomarkers and tests across the entire care pathway.
The retained eleven use cases — and the subset identified as highest priority — provide explicit targets for biomarker discovery, diagnostic development, and investment decisions.
Applying the framework to assess the existing biomarker pipeline is recommended to address gaps and accelerate translation of promising candidates into fit‑for‑purpose diagnostic tools.
Posted: September 04, 2026. Funding: Wellcome Trust. No new patient data were generated and formal IRB review was not required for the consensus methods used in this study.